Concepedia

Author

Yu Gu

Chinese Academy of Medical Sciences & Peking Union Medical CollegeORCID

Also Known As

Gu, Yu, Renhua Shi, Y Gu, Y L. Gu, Y. Gu, YU Gu, Yibo Gu, Yu GU, Yu Gu, Yu Lan Gu

103

Publications

2K

Citations

21

H-Index

59

Concepts

All Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical CollegePeking Union Medical College HospitalNational Clinical Research Center for Digestive DiseasesUniversity of Illinois Urbana-ChampaignMoffitt Cancer Center
YG

About

Yu Gu is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

950

2

Engineering

2

2

164

3

Health Sciences

1

1

14

4

Natural Sciences

1

1

14

5

Biomedical Engineering

1

1

149

Yu Gu

×

26

Publications

1.4K

Citations

16

H-Index

YearCitations

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Scott Antonia, Sarah B. Goldberg, Ani Sarkis Balmanoukian,

The Lancet Oncology

2016

589

Dual‐Locking Nanoparticles Disrupt the PD‐1/PD‐L1 Pathway for Efficient Cancer Immunotherapy

Zhanzhan Zhang, Qixue Wang, Qi Liu,

Advanced Materials

2019

149

Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial

Hongyan Cheng, Liju Zong, Yujia Kong,

The Lancet Oncology

2021

78

Inertial-Electrostatic Confinement Neutron/Proton Source

George H. Miley, J. Javedani, Yasushi Yamämoto,

AIP conference proceedings

1994

69

Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools

Qi Kong, Yue Wu, Yu Gu,

Biomedicine & Pharmacotherapy

2020

55

Detection of Cytokeratin 19, Human Mammaglobin, and Carcinoembryonic Antigen-Positive Circulating Tumor Cells by Three-Marker Reverse Transcription-Pcr Assay and Its Relation to Clinical Outcome in Early Breast Cancer

Yan Chen, Tian Ning Zou, Zhi Ping Wu,

The International Journal of Biological Markers

2010

47

Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.

Scott Antonia, Sarah B. Goldberg, Ani Sarkis Balmanoukian,

Journal of Clinical Oncology

2015

45

Orally Administered DNA Vaccine Delivery by Attenuated Salmonella typhimurium Targeting Fetal Liver Kinase 1 Inhibits Murine Lewis Lung Carcinoma Growth and Metastasis

Shuguang Zuo, Yan Chen, Zhi Ping Wu,

Biological and Pharmaceutical Bulletin

2010

36

Systematic Lymph Node Dissection May Be Abolished in Patients With Apparent Early-Stage Low-Grade Mucinous and Endometrioid Epithelial Ovarian Cancer

Jiayu Chen, Jie Yin, Yan Li,

Frontiers in Oncology

2021

27

An Antibody-like Polymeric Nanoparticle Removes Intratumoral Galectin-1 to Enhance Antitumor T-Cell Responses in Cancer Immunotherapy

Yu Gu, Yu Zhao, Zhanzhan Zhang,

ACS Applied Materials & Interfaces

2021

25

Page 1